古塞奇尤单抗(Guselkumab) - 药物靶点：IL-23p19_在研适应症：活动性中度克罗恩病，活动性重度克罗恩病，活动性中度溃疡性结肠炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Guselkumab (Genetical Recombination)、Guselkumab (genetical recombination) (JAN)、Guselkumab (USAN)

+ [8]

靶点

IL-23p19

作用方式

抑制剂

作用机制

IL-23p19抑制剂(白细胞介素-23亚单位p19抑制剂)

治疗领域

免疫系统疾病感染遗传病与畸形+ [5]

在研适应症

活动性中度克罗恩病活动性重度克罗恩病活动性中度溃疡性结肠炎+ [24]

非在研适应症

腺瘤性结肠息肉病乳糜泻泛发性脓疱型银屑病+ [5]

原研机构

Janssen Global Services LLC

在研机构

Janssen-Cilag International NV

Janssen Pharmaceutica NV

Janssen Biotech, Inc.

+ [11]

非在研机构-

权益机构

Janssen Pharmaceuticals, Inc.

Celsius Therapeutics, Inc.

MorphoSys AG

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2017-07-13),

斑块状银屑病

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)、突破性疗法 (中国)、孤儿药 (日本)、临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

Sequence Code 9493545H

来源: *****

Sequence Code 9493571L

来源: *****

关联

114

项与古塞奇尤单抗相关的临床试验

NCT07448402

/ Not yet recruitingN/AIIT

National Registry of Patients With Psoriatic Disease Receiving Interleukin-23 Inhibitor Therapy Within the Costa Rican Social Security System

The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:
* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice?
* What is the safety profile and treatment persistence of IL-23 inhibitors in this population?
* Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.

开始日期2026-05-01

申办/合作机构-

CTIS2025-524573-16-00

/ Not yet recruiting临床4期

OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE

开始日期2026-04-30

申办/合作机构

Getaid

NCT06916390

/ Recruiting临床4期IIT

Guselkumab Intervention and Diet Evaluation for Pouchitis

Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy or with neoplasia. The most common complication after IPAA is the development of pouchitis. Pouchitis is clinically characterized by variable symptoms including increased stool frequency, altered consistency, bloody stools, abdominal cramping, urgency, and incontinence. Symptomatic pouchitis longer than four weeks is considered chronic pouchitis.
The conventional treatment for acute and chronic pouchitis is antibiotics, such as metronidazole and ciprofloxacin. The disease course of antibiotic responsive pouchitis may evolve into antibiotic dependent (requiring antibiotic maintenance therapy) pouchitis and then antibiotic refractory (no response to antibiotic treatment) pouchitis. Although many patients respond to antibiotic therapy, there is also evidence that suggest that aberrant regulation of the mucosal immune system might play a part in the pathogenesis of pouchitis arising from an abnormal mucosal immune response to a dysbiosis of the pouch microbiota. If individuals fail to respond to antibiotics, anti-tumor necrosis factor (anti-TNF) agents and vedolizumab have been proposed for the treatment of chronic pouchitis.
Guselkumab, an interleukin-23 (IL-23) p19 subunit antagonist monoclonal antibody, is proven to be efficacious in patients with moderately-to-severely active UC. Efficacy of guselkumab in treating UC has been shown in multiple large clinical trials. However, patients with pouchitis were never the targeted population and were even often excluded from the trials.
Pouchitis becomes a chronic problem with a huge impact in the quality of life of these patients. The incidence of pouchitis has been rising in the last decades. This increase might be explained by a change in dietary habits of this population.
This open label single center trial at UZ Leuven aims to evaluate the efficacy and safety of guselkumab in the treatment of chronic antibiotic refractory pouchitis during a 48-week treatment period, with or without a dietary intervention. Twenty subjects with a proctocolectomy and IPAA for UC who have developed chronic or relapsing pouchitis will be enrolled.

开始日期2026-04-23

申办/合作机构

Universitaire Ziekenhuizen KU Leuven

100 项与古塞奇尤单抗相关的临床结果

登录后查看更多信息

100 项与古塞奇尤单抗相关的转化医学

登录后查看更多信息

100 项与古塞奇尤单抗相关的专利（医药）

登录后查看更多信息

845

项与古塞奇尤单抗相关的文献（医药）

2026-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Article

作者: Zhdanava, Maryia ; Fitzgerald, Timothy ; Feldman, Steven R. ; Boonmak, Porpong ; Schwartzbein, Samuel ; Libchaber, Béatrice ; Pilon, Dominic

OBJECTIVE:

To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.

MATERIALS AND METHODS:

This retrospective cohort study used U.S. claims data from the IQVIA PharMetrics® Plus database (2016- 2023). Overlap propensity score weights were used to balance cohorts on baseline characteristics. On-label persistence was defined as the absence of drug discontinuation (event) and any dose change relative to the U.S. label (censoring). Survival analyses were used to assess on-label persistence from the start of the maintenance phase.

RESULTS:

At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001).

CONCLUSIONS:

Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.

2026-05-01·INFLAMMATORY BOWEL DISEASES

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Article

作者: Vetter, Marion L ; Van Rampelbergh, Rian ; Andrews, Jane M ; Corbett, Christopher ; Panaccione, Remo ; Sands, Bruce E ; Panés, Julián ; Terry, Nat A ; Afzali, Anita ; Salese, Leonardo ; van Duijnhoven, Wilbert ; Yee, Jacqueline ; Hisamatsu, Tadakazu ; Reinisch, Walter ; D'Haens, Geert R ; Danese, Silvio ; Rubin, David T

BACKGROUND:

The randomized, phase 2 GALAXI 1 study evaluated efficacy and safety of guselkumab, a dual-acting IL-23p19 subunit inhibitor, in participants with moderately to severely active Crohn's disease. Efficacy and safety through 5 years are reported.

METHODS:

After completing the 48-week, treat-through GALAXI 1 main study, participants could enter the long-term extension (LTE) and continue the subcutaneous maintenance regimen assigned at randomization. Efficacy for the combined guselkumab dose groups was analyzed by (1) as-observed analysis of LTE participants, (2) nonresponder imputation (NRI) analysis of LTE participants, and (3) NRI analysis of primary efficacy analysis set (all [week 0] randomized participants). The study was not designed for statistical comparisons between groups.

RESULTS:

Of 185 guselkumab-randomized participants in the primary efficacy analysis set, 151 participated in the LTE. Among those continuing treatment, with available data (as observed), 97.7% (n = 85 of 87) achieved clinical remission, 71.3% (n = 62 of 87) achieved endoscopic response, and 51.7% (n = 45 of 87) achieved endoscopic remission at week 240. Results from NRI analyses also showed durability of efficacy (eg, week-240 clinical remission: 59.2% [n = 84 of 142], LTE analysis set; 46.0% [n = 81 of 176], primary efficacy analysis set). High rates of clinical and endoscopic remission at week 240 were maintained in biologic-naive participants (97.8% [n = 45 of 46] and 54.3% [n = 25 of 46], respectively [as-observed]) and participants with an inadequate response or intolerance to biologic therapy (97.1% [n = 34 of 35] and 54.3% [n = 19 of 35], respectively [as-observed]). Event rates of serious adverse events, discontinuations due to adverse events, and serious infections were low in guselkumab-treated participants.

CONCLUSIONS:

Long-term guselkumab treatment showed sustained clinical and endoscopic efficacy through week 240. The long-term safety data were consistent with those previously presented in approved indications.

CLINICAL TRIAL REGISTRATION:

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI), NCT03466411, https://clinicaltrials.gov/study/NCT03466411.

2026-05-01·INTERNATIONAL JOURNAL OF DERMATOLOGY

Super‐Response to Guselkumab Treatment in Patients With Moderate‐to‐Severe Psoriasis: Real‐World Data With Up to Five Years of Follow‐Up in The Czech Republic

Article

作者: Tomas Dolezal ; Petra Cetkovska ; Spyridon Gkalpakiotis ; Alena Machovcova ; Martina Kojanova ; Petr Arenberger ; Martin Tichy ; Daniela Pejrilova ; Jorga Fialova ; Jiri Stork ; the BIOREP study group

ABSTRACT:

Background:

Guselkumab, a selective interleukin (IL)‐23 inhibitor, is approved for the treatment of moderate‐to‐severe plaque psoriasis. While randomized clinical trials have introduced the concept of “super‐responders” (SRe)—patients achieving complete skin clearance (Psoriasis Area and Severity Index [PASI] 100) at defined early timepoints—real‐world evidence on their characteristics and long‐term outcomes remains limited. This study aimed to identify baseline predictors of super‐response (PASI 100 at Weeks 16 and 24) and to evaluate long‐term effectiveness, safety, and drug survival over a 5‐year period in a routine clinical setting.

Methods:

This retrospective multicenter study analyzed 435 patients from the Czech BIOREP registry treated with guselkumab. Predictors of super‐response were identified using multivariable logistic regression. PASI outcomes and drug survival were assessed with descriptive statistics and Kaplan–Meier analysis.

Results:

Among the cohort, 130 patients (29.9%) were classified as super‐responders. Lower body mass index (BMI) and absence of prior biologic therapy were independent predictors of SRe status (odds ratio [OR] = 0.94 and 0.73, respectively). While PASI 75/90/100 rates were significantly higher in SRe throughout follow‐up, drug survival was comparable between SRe and non‐SRe. At 60 months, PASI 100 was maintained in 79.2% of SRe versus 35.4% of non‐SRe. Obesity and female sex were associated with lower long‐term treatment persistence.

Conclusions:

Super‐response to guselkumab is linked to distinct baseline features. Despite differences in PASI outcomes, treatment persistence was similar across groups. These findings underscore the value of early identification of super‐responders and support personalized treatment strategies in clinical practice.

1,340

项与古塞奇尤单抗相关的新闻（医药）

2026-05-19

·百度百家

治疗头皮银屑病哪种生物制...@皮肤科杨高云医生的动态

治疗头皮银屑病哪种生物制剂效果好？头皮银屑病治疗中，生物制剂通过靶向免疫通路有效控制炎症，尤其对中重度患者效果显著。建议在医生评估后选择适合的制剂，并定期监测疗效与安全性。 1、生物制剂作用机制生物制剂如IL-17和IL-23抑制剂，能精准阻断银屑病相关的炎症信号，减少头皮鳞屑和红斑，缓解瘙痒。 2、常用生物制剂类型包括司库奇尤单抗、依奇珠单抗（抗IL-17）和古塞奇尤单抗（抗IL-23），临床研究显示对头皮部位疗效突出。 3、疗效与安全性对比 IL-17抑制剂起效快，通常2-4周改善症状；IL-23抑制剂长期缓解更佳，但需注意感染风险，需筛查结核。 4、个体化治疗选择医生会根据皮损严重度、关节受累、既往治疗反应及合并症，推荐最合适的生物制剂，如伴关节炎优先选TNF-α抑制剂。 5、治疗注意事项治疗前需排除活动性感染，治疗中定期复查血常规和肝肾功能，避免活疫苗接种，孕期需调整方案。科普内容仅供参考，如有不适请线下就医，具体用药需遵医嘱。 #头皮银屑病# #生物制剂# #皮肤科治疗#

2026-05-19

·科学战银

银屑病｜同样是IL-23生物制剂，ORKA-001做了哪些升级，为何能实现“一年一针”？

点击上面文字添加关注!推荐指数★★★★★ 【伊顿健康导读】现在临床上用来治银屑病的生物制剂里，针对IL-23靶点的几款用药，主要有古塞奇尤单抗、替瑞奇珠单抗、匹康奇拜单抗等，这几款均已在中国上市。这类生物制剂因长期疗效稳定、良好的安全性，以及更低的打针频率，已成为不少中重度斑块状银屑病患者的倾向选择方案。针对这一点，有没有可能出现更低的打针频率呢？近期，ORKA-001这款新型IL-23p19抑制剂，公布了积极的临床数据，发现它竟然实现了“一年一针” 的长效结果。那么，它究竟做了哪些关键升级呢？其超长效的原理又是什么？革命性的长效化技术改造现有IL-23抑制剂的半衰期，也就是药物在体内有效浓度维持的时间，通常在一个月内，这也决定了它的给药间隔。ORKA-001属于IL-23p19单克隆抗体，最大的突破在于，研究者使用了YTE半衰期延长技术，对其结构进行了优化改造，其半衰期延长至约100天。这意味着单次注射后，药物在患者体内能够维持治疗浓度的时间远超现有药物。正是基于这一超长的半衰期，才使得“一年一针” 的给药方案成为可能。这无疑是给药频率上的一次质的飞跃。在疗效目标上表现也很突出除了给药便利性，疗效是衡量升级成功与否的重要指标。在近期发布的EVERLAST-A的2a期临床试验中，ORKA-001展现了令人瞩目的数据：在接受治疗的患者中，高达63.5%的人在第16周就实现了PASI 100，即皮肤的完全清除。另外有82.5%的患者达到PASI 90的治疗目标。这些目标数据在目前已上市的IL-23抑制剂中也处于非常高的水平。安全性与耐受性依然良好 ORKA-001在其安全性方面，与现有IL-23p19抑制剂类药物差不多。在临床试验中，其耐受性良好，安全性与安慰剂相似。未报告严重的治疗相关不良事件，大多数不良事件为轻度，另外未发生注射部位反应。总结可以看出，ORKA-001的升级是一个“疗效-长效-安全”的协同提升。它的出现代表了银屑病生物制剂研发的一个重要方向：在不断提升疗效标准的同时，通过技术创新极大优化治疗体验，让患者未来能够以更简单的方式，获得更持久的病情控制。当然，ORKA-001仍需更大规模的3期临床试验来进一步验证其长期疗效和安全性。感谢阅读，希望内容能对你有所帮助。临床前沿资讯：如今银屑病领域创新药研发飞速发展，除临床常用的 IL-17A 生物制剂外，TYK2 抑制剂、IL-23 抑制剂、JAK 抑制剂等多个靶点，均有大量临床研究持续推进。感兴趣的患者可以发送“临床”到公众号，参与评估。参考文献： 1.ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis (EVERLAST-A). Identifier: NCT06384207. Available from: https://clinicaltrials.gov/study/NCT06384207 2.Robbie, G. J., et al. (2013). A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrobial Agents and Chemotherapy, 57(12), 6147–6153. 3.Blauvelt, A., et al. (2017). Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis: Integrated Analysis of the Phase 3 Trials. 本文仅做参考，不构成对任何药物或诊疗方案的推荐、推广或宣传，也不可替代专业医疗建议。如有问题，请咨询医疗卫生专业人士。材料图片等源自网络，侵删。

2026-05-19

·银消帮

【无安慰剂】有机会直接打特诺雅！银屑病临床正在开展！全国多地就近安排！

点击蓝字关注我们导读目前正在开展一项在中重度斑块状银屑病患者中比对QL2106注射液与特诺雅®的有效性和安全性的多中心、随机、双盲、平行、阳性对照III期临床研究。药物介绍 QL2106注射液是齐鲁制药研发的一款针对中重度斑块状银屑病的生物制剂，属于IL-23抑制剂的生物类似药。通过在发病机制上游阻断致病信号，从而抑制炎症、改善皮损。临床介绍项目用药：QL2106注射液适应症：中重度斑块状银屑病临床期数：III期临床周期：52周主要入组标准 1. 年龄≥18 周岁，男女不限； 2. 随机前诊断为斑块状银屑病≥6 个月（合并或不合并银屑病关节炎）； 3. 适合接受系统治疗或光疗； 4. 筛选期和基线时满足以下标准：银屑病面积和严重程度评分（PASI）≥12分，研究者整体评分（IGA）≥3 分，体表受累面积（BSA）≥10%； 5. 受试者及其伴侣自签署知情同意书至末次试验用药品给药后 3 个月内无捐精或捐卵计划、无妊娠计划且自愿采取有效的避孕措施（见错误!未找到引用源。） 6. 理解并遵守研究程序和方法，自愿参加本试验，并书面签署知情同意书。以上为主要入选标准，最终是否入选由研究者判断排除标准 1.已知对古塞奇尤单抗或其辅料过敏者，或曾对单克隆抗体有严重过敏反应，经研究者判断有严重过敏风险的受试者； 2.患有点滴状银屑病、脓疱型银屑病、红皮病型银屑病、药物性银屑病（如 β受体阻滞剂或锂制剂等药物引起的新发或银屑病加重），或其他影响治疗结果的疾病（皮肤病变或其他系统性自身免疫疾病等）； 3.筛选期出现以下异常检查结果者，如研究者认为有必要，可复查一次： a)血常规：血红蛋白（HGB）<90 g/L、血小板计数（PLT）<100×109/L、白细胞（WBC）<3×10 9 /L、中性粒细胞绝对值（NEUT）<1.5×10 9 /L； b)肝功能：丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）、碱性磷酸酶（ALP）＞2×ULN； c)肾功能：血清肌酐（SCR）＞1.5×ULN； 4.伴有严重、进展性或无法控制的中枢神经系统、心血管系统、消化系统、内分泌系统、呼吸系统、泌尿系统、血液系统等系统性疾病者，经研究者评估认为不适合参加本临床研究； 5.伴有不稳定的心脑血管疾病，定义为筛选前 3个月内出现疾病加重（如不稳定型心绞痛、心房纤颤、脑出血、急性脑梗死等）或在筛选前 3个月内因心脑血管疾病接受住院治疗； 6. 既往曾患淋巴细胞增生类疾病，包括淋巴瘤或潜在淋巴增生性疾病的症状和体征；以上为主要排除标准，最终是否入选由研究者判断临床地区上海、成都、杭州、嘉兴、镇江、蚌埠、铜陵、盐城、合肥、常州、无锡、遂宁、曲靖、宝鸡、昆明、重庆、南宁、邯郸、邢台、天津、北京、沈阳、石家庄、哈尔滨、长春、广州、韶关、福州、长沙、郑州、荆州、济南、洛阳、常德、济宁、海口、驻马店、西安、长治、乌鲁木齐、太原、柳州。等地的三甲医院，可就近安排，避免奔波劳累如果您或身边有符合条件的中重度斑块状银屑病患者，不妨关注一下这个项目，成功入组后，不收取治疗费用，临床皆在上述地区的三甲医院开展，安全有保证！点击下方图片申请用药报名 ↓ ↓ ↓（报名后注意北京地区来电）

100 项与古塞奇尤单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10438	古塞奇尤单抗	L04AC16	DB11834

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
活动性中度克罗恩病	中国	Janssen-Cilag International NV	2025-02-20
活动性重度克罗恩病	中国	Janssen-Cilag International NV	2025-02-20
活动性中度溃疡性结肠炎	美国	Janssen Biotech, Inc.	2024-09-11
活动性重度溃疡性结肠炎	美国	Janssen Biotech, Inc.	2024-09-11
手掌和足底脓疱病	日本	Janssen Pharmaceutical KK	2018-11-21
溃疡性结肠炎	韩国	Janssen Korea Ltd.	2018-04-12
克罗恩病	韩国	Janssen Korea Ltd.	2018-04-12
掌跖角化病	韩国	Janssen Korea Ltd.	2018-04-12
红皮病性银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
脓疱型银屑病	日本	Janssen Pharmaceutical KK	2018-03-23
银屑病关节炎	欧盟	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	冰岛	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	列支敦士登	Janssen-Cilag International NV	2017-11-10
银屑病关节炎	挪威	Janssen-Cilag International NV	2017-11-10
斑块状银屑病	美国	Janssen Biotech, Inc.	2017-07-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
幼年特发性关节炎	申请上市	美国	Johnson & Johnson	2024-12-02
小儿克罗恩病	临床3期	美国	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	日本	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	澳大利亚	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	奥地利	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	比利时	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	巴西	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	加拿大	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	法国	Janssen Research & Development LLC	2024-03-13
小儿克罗恩病	临床3期	以色列	Janssen Research & Development LLC	2024-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03466411 (GALAXI 1, Pubmed \| Inflamm Bowel Dis)	临床2期	克罗恩病	185	Guselkumab	鏇繭網簾網艱鹽範艱餘(觸鬱鬱鹽膚鬱繭憲糧願) = 艱艱艱鏇願糧製醖窪餘襯鬱願淵醖壓壓憲觸積 (壓蓋網鹽鏇齋艱蓋構齋 ) 更多	积极	2026-05-01
				Guselkumab (LTE participants)	鏇繭網簾網艱鹽範艱餘(觸鬱鬱鹽膚鬱繭憲糧願) = 鏇壓構觸衊襯鏇齋憲壓襯鬱願淵醖壓壓憲觸積 (壓蓋網鹽鏇齋艱蓋構齋 )
NCT06039189 (SPECTREM, CTgov)	临床3期	斑块状银屑病	338	Placebo+Guselkumab (Group 1: Placebo Followed by Guselkumab 100 mg)	遞繭獵醖壓淵鬱餘遞觸 = 積獵衊淵憲鬱簾網膚醖憲醖繭簾壓鏇築齋艱鑰 (繭廠鹽觸築襯艱鹽鹹顧, 膚蓋鹽醖膚鏇願繭遞廠 ~ 網鹹顧糧膚衊繭築選鏇) 更多	-	2026-05-01
				Guselkumab (Group 2: Guselkumab 100 mg)	遞繭獵醖壓淵鬱餘遞觸 = 鹽遞襯膚積壓鏇淵壓積憲醖繭簾壓鏇築齋艱鑰 (繭廠鹽觸築襯艱鹽鹹顧, 齋顧築襯壓簾淵齋繭憲 ~ 夢糧鑰鬱壓廠製簾積壓) 更多
NCT05528510 (ASTRO, Pubmed \| Lancet Gastroenterol Hepatol)	临床3期	溃疡性结肠炎	418	Guselkumab 400/100 mg	願廠糧窪獵繭製鹹艱艱(獵齋蓋襯遞繭膚餘鏇糧) = 餘窪顧鑰鏇蓋選餘網獵襯窪醖廠範築襯選鹹齋 (獵鹽鏇構範遞醖網淵廠 ) 更多	积极	2026-04-01
				Guselkumab 400/200 mg	願廠糧窪獵繭製鹹艱艱(襯簾製夢鑰鬱鹽夢鹽齋) = 蓋壓憲獵築顧鏇窪鏇觸遞鹹夢糧製鬱鹽淵襯憲 (衊鏇鏇憲遞鏇觸網範鏇 ) 更多
VOYAGE 1 (AAD2026)	临床3期	斑块状银屑病	643	Guselkumab	壓鑰範醖觸膚鏇鏇餘憲(壓糧糧構壓製範選願艱) = 網鏇鏇壓鏇獵壓鏇夢製願窪壓鹹簾築鹽築窪顧 (膚憲顧廠蓋願構顧築艱 ) 更多	积极	2026-03-27
AAD2026	N/A	银屑病 \| 类风湿关节炎	32	TNF- inhibitors (Systemic treatment)	願廠選醖壓網簾簾築夢(鑰網鏇蓋選夢壓簾觸鹽) = 壓淵鹹築製淵鬱鹹鏇醖艱築蓋構選築鬱壓鬱繭 (構積獵衊鹽衊蓋窪網築 )	积极	2026-03-27
				methotrexate (Systemic treatment)	築構網餘鹹構網憲鬱襯(遞夢壓積壓窪憲壓鏇壓) = 廠鹹憲壓衊衊簾淵遞醖餘蓋製膚選憲鹹艱製醖 (簾網膚構糧構蓋積餘壓 )
AAD2026	N/A	银屑病	40	Guselkumab	積鏇繭廠顧廠鑰醖鹹夢(範蓋膚餘鹽壓鑰顧夢獵) = 選壓餘鹹構窪鏇構製壓繭蓋築齋築簾願簾積願 (膚製夢壓選鬱積鹹鏇網 ) 更多	积极	2026-03-27
G-REAL (AAD2026)	N/A	银屑病一线	502	Guselkumab (biologic-naive)	壓觸網顧艱構廠鏇襯蓋(餘鏇齋繭膚餘衊壓壓衊) = 製範廠構糧壓獵遞膚願夢醖鹽積襯選獵蓋窪願 (蓋膚製簾獵鑰鹽廠衊夢 ) 更多	积极	2026-03-27
				Guselkumab (one prior biologic)	壓觸網顧艱構廠鏇襯蓋(餘鏇齋繭膚餘衊壓壓衊) = 廠淵夢範蓋積淵繭鹽餘夢醖鹽積襯選獵蓋窪願 (蓋膚製簾獵鑰鹽廠衊夢 ) 更多
VISIBLE (AAD2026)	临床3期	斑块状银屑病	103	Guselkumab 100mg	齋積觸壓鑰壓範獵鑰鹽(願獵餘築鹹廠糧積襯繭) = 簾窪蓋築衊襯製積壓獵獵觸鹹遞淵窪簾襯顧齋 (網艱觸網獵蓋範鹽繭範 ) 更多	积极	2026-03-27
				Placebo	築糧構淵窪遞衊獵淵願(網鏇蓋窪襯製構鹽淵壓) = 廠膚顧鑰糧鑰壓醖鑰蓋遞積繭築蓋齋鹹鬱簾鏇 (餘獵鹽壓網觸願襯窪簾 ) 更多
AAD2026	N/A	银屑病	26	Adalimumab	繭襯鹽範齋繭鹽壓顧製(鏇繭鬱衊遞膚鑰艱壓鏇) = 遞齋積廠醖糧築獵衊膚鬱鑰蓋繭顧顧襯觸窪膚 (鏇窪憲淵蓋鹽衊餘製獵 ) 更多	积极	2026-03-27
				Infliximab	繭襯鹽範齋繭鹽壓顧製(鏇繭鬱衊遞膚鑰艱壓鏇) = 遞鏇積觸鬱願鑰鹽鑰顧鬱鑰蓋繭顧顧襯觸窪膚 (鏇窪憲淵蓋鹽衊餘製獵 ) 更多
APEX (AAD2026)	临床3期	银屑病关节炎	1,120	Guselkumab Q4W	淵鹽構願遞觸鹽壓製遞(蓋簾簾簾鏇顧製鬱齋網) = 膚壓夢餘糧積窪齋衊積網選襯積鬱壓鏇齋襯壓 (築憲願壓艱顧獵餘蓋襯 ) 更多	积极	2026-03-27
				Guselkumab Q8W	淵鹽構願遞觸鹽壓製遞(蓋簾簾簾鏇顧製鬱齋網) = 範製膚觸鬱繭鹹範醖獵網選襯積鬱壓鏇齋襯壓 (築憲願壓艱顧獵餘蓋襯 ) 更多